Detail akcie Antigenics online

Business Summary: Antigenics Inc., formerly Agenus Inc., is an immunotherapy company. The Company is developing a series of checkpoint modulators (CPM) for the treatment of patients with cancer, infectious diseases, and other immune disorders; heat shock protein (HSP)-based vaccines, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Retrocyte Display (Retroviral B Lymphocyte Display) is an antibody discovery platform designed for the discovery and optimization of fully human and humanized monoclonal antibodies against an array of molecular targets. Its HSP-based vaccine platform includes its Prophage Series vaccine candidates for the treatment of cancer and its HerpV vaccine candidate for the treatment of genital herpes. Its pipeline of product candidates containing QS-21 Stimulon includes vaccines for infectious diseases, cancer types and Alzheimer's disease.
Financial Summary: BRIEF: For the three months ended 31 March 2001, Antigenics Inc revenues decreased 94% to $92K. Net loss before extraordinary items increased 33% to $3.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Sale of Investment decrease from $2.7M (income) to $0K, Interest Income decrease of 52% to $106K (income).